lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed and are posted here as part of a 12-month trial. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com

Hydrogen Gas Inhalation Alleviates Radiation-Induced Bone Marrow Damage in Cancer Patients

16 Pages Posted: 11 Mar 2019

See all articles by Shin-ichi Hirano

Shin-ichi Hirano

MiZ Company Limited

Yukimasa Aoki

Clinic C4

Ryosuke Kurokawa

MiZ Company Limited

Xiao-Kang Li

National Institute for Child Health and Development

Naotsugu Ichimaru

Osaka University - Department of Advanced Technology for Transplantation

Shiro Takahara

Kansai Medical Hospital

Yoshiyasu Takefuji

Keio University - Faculty of Environment and Information Studies

More...

Abstract

Background: Radiotherapy for cancer patients is one of the useful methods; however, it not only impairs the targeted tumor tissues but also damage the normal surrounding tissues. Intensity modulated radiation therapy (IMRT) for cancer patients has been recently performed to alleviate the adverse effects, but reducing bone marrow damage is limited in the patients with multiple tumor lesions and large irradiation volume. Molecular hydrogen (H2) was recently reported as a preventive and therapeutic antioxidant that selectively scavenges hydroxy radical (*OH) and peroxynitrite (ONOO-). This observational study aims to examine whether H2 gas treatment improves IMRT radiation-induced bone marrow damage in cancer patients.    

Methods: The patients with end stage of cancer were received IMRT once per day for 1 to 4 weeks except Saturday and Sunday. After each IMRT, the patients of control group (n = 7) were housed in health care chamber (HCC, mild hyperbaric oxygen chamber) for 30 minutes, and the patients of H2 group (n = 16) were also housed in HCC and received 5% H2 gas for 30 minutes once per day. Radiation-induced bone marrow damage was evaluated by hematological examination of peripheral blood obtained before and after IMRT.    

Results: IMRT with HCC therapy significantly reduced white blood cells (WBC) and platelets (PLT) respectively, but not red blood cells (RBC), hemoglobin (HGB) and hematocrit (HT). In contrast, H2 gas treatment significantly alleviates reducing effects of WBC and PLT respectively. There was no difference in anti-tumor effects between the two groups.    

Interpretation: Our study demonstrated that H2 gas inhalation therapy significantly alleviates IMRT radiation-induced bone marrow damage without compromising anti-tumor effects. These results suggest that H2 gas treatment would be a strategy for reducing IMRT bone marrow damage in cancer patients.   

Funding: Self-funding.

Declaration of Interest: NI and ST are supported by a grant from MiZ Company Limed. The other authors declare that they have no competing interests.

Ethical Approval: The study protocol and materials were approved by ethics committee review by ICVS Tokyo Clinic (Tokyo, Japan), and all subjects provided written informed consent prior to the therapy.

Suggested Citation

Hirano, Shin-ichi and Aoki, Yukimasa and Kurokawa, Ryosuke and Li, Xiao-Kang and Ichimaru, Naotsugu and Takahara, Shiro and Takefuji, Yoshiyasu, Hydrogen Gas Inhalation Alleviates Radiation-Induced Bone Marrow Damage in Cancer Patients (March 8, 2019). Available at SSRN: https://ssrn.com/abstract=3349228

Shin-ichi Hirano

MiZ Company Limited ( email )

Kanagawa
Japan

Yukimasa Aoki

Clinic C4 ( email )

Tokyo
Japan

Ryosuke Kurokawa

MiZ Company Limited ( email )

Kanagawa
Japan

Xiao-Kang Li

National Institute for Child Health and Development ( email )

Tokyo
Japan

Naotsugu Ichimaru

Osaka University - Department of Advanced Technology for Transplantation ( email )

2-2 J8, Yamadaoka, Suita
Osaka, 565-0871
Japan

Shiro Takahara

Kansai Medical Hospital ( email )

Osaka
Japan

Yoshiyasu Takefuji (Contact Author)

Keio University - Faculty of Environment and Information Studies ( email )

Endo
Japan

Click here to go to TheLancet.com

Go to TheLancet.com

Paper statistics

Abstract Views
564
Downloads
95